Segment Data (Tables)

3 Months Ended

Apr. 01, 2022

Schedule of Segment Reporting Information by Reportable Segment

Selected information by reportable segment was as follows:


	Three Months Ended
	April 1, 2022		March 26, 2021
Net sales:
Specialty Brands	$	339.4	$	408.4
Specialty Generics	151.5		149.6
Net sales	$	490.9	$	558.0
Operating income (loss):
Specialty Brands	$	164.8	$	212.1
Specialty Generics	34.4		31.7
Segment operating income	199.2		243.8
Unallocated amounts:
Corporate and unallocated expenses (1)	(32.8)		(22.6)
Depreciation and amortization	(177.2)		(169.6)
Share-based compensation	(1.2)		(3.6)
Restructuring charges, net	(6.8)		(0.4)
Non-restructuring impairment charges	—		(64.5)
Separation costs (2)	(2.0)		(0.6)



Operating loss	$	(20.8)	$	(17.5)

(1)Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

(2)Represents costs included in selling, general and administrative expenses, primarily related to professional fees and costs incurred as the Company explores potential sales of non-core assets to enable further deleveraging post-emergence.

Schedule of Net Sales from External Customers by Products

Net sales by product family within the Company's reportable segments were as follows:


	Three Months Ended
	April 1, 2022		March 26, 2021
Acthar Gel	$	127.7	$	129.0
INOmax	99.0		134.0
Ofirmev	2.6		12.8
Therakos	59.9		66.8
Amitiza (1)	47.7		61.4
Other	2.5		4.4
Specialty Brands	339.4		408.4

Hydrocodone (API) and hydrocodone-containing tablets	19.0		23.3
Oxycodone (API) and oxycodone-containing tablets	16.6		17.2
Acetaminophen (API)	46.3		45.5
Other controlled substances	64.1		58.1
Other	5.5		5.5
Specialty Generics	151.5		149.6
Net sales	$	490.9	$	558.0

(1)Amitiza consists of both product net sales and royalties. Refer to Note 2 for further details on Amitiza's revenues.